Voyager Therapeutics (VYGR) Net Income (2014 - 2026)
Voyager Therapeutics (VYGR) posted Net Income of -$27.9 million for Q1 2026, down 1.86% sequentially from -$27.4 million in Q4 2025, and up 9.94% YoY from -$25.4 million in Q1 2025.
Voyager Therapeutics (VYGR) Net Income (2014 - 2026) Analysis & Trends
Voyager Therapeutics has reported Net Income for 13 years, with the latest figure at -$27.9 million in Q1 2026.
- Quarterly Net Income rose 9.94% year-over-year to -$27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$116.6 million (down 38.52% YoY) and the FY2025 annual result came in at -$119.7 million, down 85.58% from the prior year.
- Net Income fell to -$27.9 million in Q1 2026 per VYGR's latest filing, from -$27.4 million in the prior quarter.
- Over five years, Net Income peaked at $124.0 million in Q1 2023 and troughed at -$34.0 million in Q4 2024.
- A 5-year average of -$7.3 million and a median of -$22.2 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2023: Net Income plunged 515.6% in 2022, then surged 681.85% in 2023.
- Over 5 years, Net Income stood at -$23.6 million in 2022, then surged by 344.34% to $57.7 million in 2023, then plunged by 158.93% to -$34.0 million in 2024, then increased by 19.33% to -$27.4 million in 2025, then fell by 1.86% to -$27.9 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$27.9 million, -$27.4 million, and -$27.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.93 Bn | 131.07 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.92 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.72 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.88 Bn | 9.49 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 81.49 Mn |
| 10 | Voyager Therapeutics | 207.38 Mn | 91.04 Mn | - | -24.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.47 Mn |
| Mar 31, 2026 | -27.94 Mn |
| Dec 31, 2025 | -27.43 Mn |
| Sep 30, 2025 | -27.89 Mn |
| Jun 30, 2025 | -33.38 Mn |
| Mar 31, 2025 | -31.02 Mn |
| Dec 31, 2024 | -34.00 Mn |
| Sep 30, 2024 | -9.04 Mn |
| Jun 30, 2024 | -10.14 Mn |
| Mar 31, 2024 | -11.33 Mn |
| Dec 31, 2023 | 57.69 Mn |
| Sep 30, 2023 | -25.90 Mn |
| Jun 30, 2023 | -22.21 Mn |
| Mar 31, 2023 | 124.04 Mn |
| Dec 31, 2022 | -23.61 Mn |
| Sep 30, 2022 | 17.62 Mn |
| Jun 30, 2022 | -19.09 Mn |
| Mar 31, 2022 | -21.32 Mn |
| Dec 31, 2021 | 5.68 Mn |
| Sep 30, 2021 | -83.74 Mn |